Raredr

Phase 3 Hepatocellular Carcinoma Trial Fails

Andrew Black
Published Online: Friday, Feb 17, 2017
A Phase 3 study of Daiichi Sankyo and ArQule’s tivantinib (ARQ 197), a designed treatment for MET-overexpressing hepatocellular carcinoma (HCC) did not meet its primary endpoint of improving overall survival in patients.
 
The Phase 3 trial was a double-blind, placebo-controlled, randomized study evaluating tivantinib in comparison to best supportive care in 340 patients with MET-overexpressing, inoperable HCC intolerant to or previously-treated with systemic therapy.
 
Unfortunately, the study did not meet its primary endpoint. Full results from the trial will be presented at an upcoming medical conference.
 
The company has seen a string of negative results for this drug, but there was a ray of light in late 2014, when it posted a positive outcome in a phase 2 metastatic prostate cancer study after hitting the primary endpoint for progression-free survival compared to a placebo.
 
We will see what the next step for tivantinib is.

About tivantinib

Tivantinib is an investigational oral inhibitor of the MET receptor tyrosine kinase. Overexpression of the MET pathway is associated with poor outcomes in many cancers, including HCC, non-small cell lung cancer (NSCLC) and others.

About Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a cancer that begins in the liver, usually in patients who have underlying chronic liver disease and scarring of the liver tissue (cirrhosis). Tumors progress with local expansion, intrahepatic spread, and distant metastases.
 
This type of cancer occurs more often in men than women. It is usually diagnosed in people age 50 or older.
 


Latest Articles
Dave Esposito, father of a child with Sanfilippo syndrome, wants the FDA and the pharmaceutical industry to know that their definition of a good outcome measure is different than a parent's definition.
Alexion announced it will stop developing SBC-103 for the treatment of Sanfilippo type B [mucopolysaccharidosis (MPS) IIIB].
A Phase 3b trial assessing agalsidase beta in pediatric Fabry disease male patients shows encouraging results.
A Phase II study testing savolitinib in locally advanced or metastatic pulmonary sarcomatoid carcinoma (PSC) has begun in China.
$vacMongoViewPlus$ $vAR$